Konjac glucomannan (KGM) is a herbal medicine with benefits in appetite control, body weight and biochemical parameters in overweight individuals. The objective of our work was to evaluate the effect of the consumption of gummy candy enriched with KGM on appetite, to evaluate anthropometric data, biochemical and oxidative stress markers in overweight individuals. Forty-two participants aged 18 to 45 years completed our randomized, double-blind, placebo-controlled clinical trial. Participants were randomly assigned to consume for fourteen days, 2 candies per day, containing 250 mg of KGM or identical-looking placebo candy with 250 mg of flaxseed meal, shortly after breakfast and dinner. As a result, we observed that there was a reduction in waist circumference and in the intensity of hunger/satisfaction of the participants who consumed KGM for fourteen days, and we believe that a longer consumption time as well as an increase dose of KGM contribute to even more satisfactory body results.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijbiomac.2022.11.232DOI Listing

Publication Analysis

Top Keywords

overweight individuals
12
candy enriched
8
konjac glucomannan
8
waist circumference
8
fourteen days
8
kgm
5
gummies candy
4
enriched konjac
4
glucomannan reduces
4
reduces hunger
4

Similar Publications

Recent studies have suggested that the interaction between diet and an individual's genetic predisposition can determine the likelihood of obesity and various metabolic disorders. The current study aimed to examine the association of dietary branched-chain amino acids(BCAAs) and aromatic amino acids(AAAs) with the expression of the leptin and FTO genes in the visceral and subcutaneous adipose tissues of individuals undergoing surgery. This cross-sectional study was conducted on 136 Iranian adults, both men and women, aged ≥18 years.

View Article and Find Full Text PDF

Diabesity is associated with a worse joint specific functional outcome following primary total knee replacement.

Arch Orthop Trauma Surg

January 2025

Department of Orthopaedics, The Royal Infirmary of Edinburgh, Little France, Edinburgh, EH16 4SA, UK.

Introduction: The combined effect of diabetes mellitus and obesity (Diabesity) on total knee replacement (TKR) outcomes is unclear. This study aimed to assess whether diabesity influenced functional outcomes and complication rate following primary TKR.

Materials And Methods: This case-controlled study compared the independent effects of obesity, diabetes, and diabesity on TKR outcomes.

View Article and Find Full Text PDF

Background: Implementation of semaglutide weight loss therapy has been challenging due to drug supply and cost, underscoring a need to identify those who derive the greatest absolute benefit.

Objectives: Allocation of semaglutide was modeled according to coronary artery calcium (CAC) among individuals without diabetes or established atherosclerotic cardiovascular disease (CVD).

Methods: In this analysis, 3,129 participants in the MESA (Multi-Ethnic Study of Atherosclerosis) without diabetes or clinical CVD met body mass index criteria for semaglutide and underwent CAC scoring on noncontrast cardiac computed tomography.

View Article and Find Full Text PDF

Objective: Globally, over 50% of the population is affected by , yet research on its prevalence and impact in patients with obesity undergoing laparoscopic sleeve gastrectomy (LSG) is inconclusive. This study aimed to assess the prevalence of infection in individuals with obesity undergoing LSG, evaluate the percentage of postoperative staple-line leaks, and explore the potential link between infection and staple-line leaks.

Methods: This retrospective analysis assessed adult patients with class III obesity who underwent LSG between 2015 and 2020 at a tertiary care hospital in Riyadh, Saudi Arabia.

View Article and Find Full Text PDF

Aim: Time-restricted eating (TRE) limits the time for food intake to typically 6-10 h/day without other dietary restrictions. The aim of the RESET2 (the REStricted Eating Time in the treatment of type 2 diabetes) trial is to investigate the effects on glycaemic control (HbA) and the feasibility of a 1-year TRE intervention in individuals with overweight/obesity and type 2 diabetes. The aim of the present paper is to describe the protocol for the RESET2 trial.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!